NASDAQ: GRTXGalera Therapeutics Inc Stock
$0.18-0.01 (-5.26%)
Updated Apr 19, 2024
GRTX Price
$0.18
Fair Value Price
N/A
Market Cap
$10.01M
52 Week Low
$0.09
52 Week High
$3.59
P/E
-0.14x
P/B
-0.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$59.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.2
Operating Cash Flow
-$45M
Beta
0.9
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GRTX Overview
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GRTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
GRTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more GRTX due diligence checks available for Premium users.
Be the first to know about important GRTX news, forecast changes, insider trades & much more!
GRTX News
Valuation
GRTX fair value
Fair Value of GRTX stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
$0.00
Overvalued by
47,050.42%
GRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GRTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
15.81x
Market
40.51x
GRTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.08x
Industry
5.74x
GRTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.6M
Profit Margin
0%
GRTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.1M
Liabilities
$157.3M
Debt to equity
-1.2
GRTX's short-term assets ($21.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRTX's long-term liabilities ($152.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.9M
Investing
$4.0M
Financing
-$232.0k
GRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRTX vs Biotech Stocks
Galera Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.